Program Description
Parkinson disease (PD) is a slowly progressing neurodegenerative disease that impacts motor-related movements early in the disease course and impairs cognitive functioning in later stages. Current dopaminergic pharmacologic therapies are only effective for symptomatic management. In the absence of an approved disease-modifying therapy for PD, pharmacists and managed care professionals must maintain familiarity with guideline recommendations for initiating pharmacotherapy for symptom management while considering each patient’s individual circumstances including symptoms, comorbidities, and risks from polypharmacy. This webinar will review current pharmacologic strategies for managing symptoms of PD as well as agents under investigation that target the underlying pathophysiology of PD to slow or halt disease progression. Strategies for managed care professionals to deliver cost-effective treatment, participate in development of clinically appropriate pathways, and ensure access to emerging treatments for PD will also be discussed.
Target audience: Managed care and specialty pharmacists
Type of activity: Application
Release date: January 30, 2023
Expiration date: March 30, 2023
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify prevalence and baseline characteristics of Parkinson disease, mechanisms of actions and targets of drug therapies, and the significant disease burden to patients and caregivers
- Investigate recent clinical updates for emerging and novel pharmacotherapeutic approaches in the treatment of Parkinson disease
- Apply the managed care considerations to appropriately assess and integrate new data to improve the care for patients with Parkinson disease
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP
Dean and Professor
Pacific University School of Pharmacy
Hillsboro, Oregon
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-629-L01-P. The activity is available for CE credit through March 30, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Lauren Assennata; Susan Pordon; Brianna Winters; and Chloe Taccetta.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms